← Leaderboards
Max Moore
Leidos Biomedical Research, Inc.
$2,587,867
Attributed
$2,587,867
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2023–24$2.5M$1.9M$1.3M$625K$0
'23
'24
Funding mix
By agency
NIH$2,587,867 · 1
By mechanism
N01$2,587,867 · 1
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- George Mitra$28,582,538
- Leonard Freedman$1,216,107,431
- Ralph Parchment$197,348,011
- Ethan Dmitrovsky$597,515,186
Others in their field
Other Rising Stars on “Pre-Clinical”
- Nancy Jean Sullivan · Boston University Medical Campus$34,500,000
- Taleen Hanania · Psychogenics, Inc.$21,254,211
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Chris Maxwell · National Institute Of Allergy And Infectious Diseases$12,000,000
Research focus
Pre-ClinicalT-Cell ActivationClinical ResearchNovel TherapeuticsProtein Sequence AnalysisResponseHuman SubjectIn SilicoContractorCd4 Positive T LymphocytesPreventProgramsRare DiseasesResearch Clinical TestingNational Center For Advancing Translational SciencesFailureImmunogenicityInnovationPreclinical DevelopmentNew TechnologyGene TherapyGene Transduction AgentCytokineTherapeutic Development
Grant awards (4)
INSILICO AND EX-VIVO IMMUNOGENICITY ANALYSIS OF NCATS GENE THERAPY TEST$564,711
N01 · FY2024 · CA · contact PI
MANUFACTURING OF TPM SUITABLE FOR HUMAN USE$1,546,809
N01 · FY2023 · CA · contact PI
INSILICO AND EX-VIVO IMMUNOGENICITY ANALYSIS OF NCATS GENE THERAPY TEST$442,590
N01 · FY2023 · CA · contact PI
STABLE CLONE PRODUCTION FOR ANTI-EBV MONOCLONAL ANTIBODIES$33,757
N01 · FY2023 · CA · contact PI